Stock Track | Omnicell Soars 8.22% Pre-market on Strong Q3 Results and Raised Guidance

Stock Track10-30

Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook. The healthcare technology company, known for its medication management solutions, demonstrated resilience in a challenging economic environment.

Omnicell reported adjusted earnings per share of $0.51 for Q3 2025, significantly beating the analyst consensus estimate of $0.36. While this represents a slight decrease from $0.56 per share in the same period last year, it showcases the company's ability to maintain profitability. Revenue for the quarter came in at $311 million, surpassing analyst expectations of $295.587 million and marking a 9.99% increase year-over-year.

The company's strong performance was primarily driven by its flagship point-of-care connected devices, along with growth in technical services, consumables, and SaaS offerings. In light of these positive results, Omnicell raised its full-year 2025 guidance, now projecting total revenues between $1.177 billion and $1.187 billion, and non-GAAP earnings per share of $1.63 to $1.73. This optimistic outlook, coupled with the company's strategic focus on transforming pharmacy care through robotics, smart devices, and analytics, has bolstered investor confidence, leading to the significant pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179085966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179085966","market":"sg","top_or_hot":-1,"title":"Stock Track | Omnicell Soars 8.22% Pre-market on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook. The healthcare technology company, known for its medication management solutions, demonstrated resilience in a challenging economic environment.</p>\n\n<p>Omnicell reported adjusted earnings per share of $0.51 for Q3 2025, significantly beating the analyst consensus estimate of $0.36. While this represents a slight decrease from $0.56 per share in the same period last year, it showcases the company's ability to maintain profitability. Revenue for the quarter came in at $311 million, surpassing analyst expectations of $295.587 million and marking a 9.99% increase year-over-year.</p>\n\n<p>The company's strong performance was primarily driven by its flagship point-of-care connected devices, along with growth in technical services, consumables, and SaaS offerings. In light of these positive results, Omnicell raised its full-year 2025 guidance, now projecting total revenues between $1.177 billion and $1.187 billion, and non-GAAP earnings per share of $1.63 to $1.73. This optimistic outlook, coupled with the company's strategic focus on transforming pharmacy care through robotics, smart devices, and analytics, has bolstered investor confidence, leading to the significant pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Soars 8.22% Pre-market on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Soars 8.22% Pre-market on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-30 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook. The healthcare technology company, known for its medication management solutions, demonstrated resilience in a challenging economic environment.</p>\n\n<p>Omnicell reported adjusted earnings per share of $0.51 for Q3 2025, significantly beating the analyst consensus estimate of $0.36. While this represents a slight decrease from $0.56 per share in the same period last year, it showcases the company's ability to maintain profitability. Revenue for the quarter came in at $311 million, surpassing analyst expectations of $295.587 million and marking a 9.99% increase year-over-year.</p>\n\n<p>The company's strong performance was primarily driven by its flagship point-of-care connected devices, along with growth in technical services, consumables, and SaaS offerings. In light of these positive results, Omnicell raised its full-year 2025 guidance, now projecting total revenues between $1.177 billion and $1.187 billion, and non-GAAP earnings per share of $1.63 to $1.73. This optimistic outlook, coupled with the company's strategic focus on transforming pharmacy care through robotics, smart devices, and analytics, has bolstered investor confidence, leading to the significant pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1179085966","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179085966","pubTimestamp":1761824549,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"个股追踪|Omnicell盘前大涨8.22%，Q3业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook. The healthcare technology company, known for its medication management solutions, demonstrated resilience in a challenging economic environment.\nOmnicell reported adjusted earnings per share of $0.51 for Q3 2025, significantly beating the analyst consensus estimate of $0.36. While this represents a slight decrease from $0.56 per share in the same period last year, it showcases the company's ability to maintain profitability. Revenue for the quarter came in at $311 million, surpassing analyst expectations of $295.587 million and marking a 9.99% increase year-over-year.\nThe company's strong performance was primarily driven by its flagship point-of-care connected devices, along with growth in technical services, consumables, and SaaS offerings. In light of these positive results, Omnicell raised its full-year 2025 guidance, now projecting total revenues between $1.177 billion and $1.187 billion, and non-GAAP earnings per share of $1.63 to $1.73. This optimistic outlook, coupled with the company's strategic focus on transforming pharmacy care through robotics, smart devices, and analytics, has bolstered investor confidence, leading to the significant pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179085966","isCrawlerRequest":true}